"Digisight Medical" Closes Nearly 100 Million RMB Series A, Leading Microsurgical Robotics | Linear Portfolio

Recently, Digisight Medical, a developer of super-microsurgical robots, closed a nearly RMB 100 million Series A round. Linear Capital led its Pre-A round and doubled down in subsequent rounds.

Founded in July 2021, Digisight Medical has maintained a leading position in technology and product development within the microsurgical robotics field. The fresh capital will accelerate regulatory clinical trials for its general-purpose microsurgical robot and commercial rollout of its ophthalmic surgical robot, further cementing the technical edge of its core products and its ecosystem of robotic micro-manipulation systems.

Recently, Hangzhou Digisight Medical Biotechnology completed a nearly RMB 100 million Series A round, led by Panlin Capital, with participation from Shangcheng Capital, Jinhe Capital, and Hangzhou Sci-Tech Innovation Group (Disruptive Technology Commercialization Fund). The proceeds will primarily go toward accelerating regulatory clinical trials for its general-purpose microsurgical robot and commercial promotion of its ophthalmic surgical robot, further strengthening Digisight Medical's technical leadership in core products and its robotic micro-manipulation product ecosystem.

Hangzhou Digisight Medical Biotechnology, founded in July 2021, is a nationally certified high-tech enterprise, a Zhejiang province "specialized and innovative" SME, and a co-builder of a Zhejiang provincial key laboratory. Its founding team hails from top institutions including Zhejiang University, Technical University of Munich, and Fortune 500 German pharmaceutical companies. To date, Digisight Medical has filed for and been granted dozens of invention patents in China and the US, and has won multiple top-tier global and domestic competition awards.

Digisight Medical has consistently held a leading position in technology and product development in microsurgical robotics. Notably, its ophthalmic surgical robot has completed China's first registration clinical trial at multiple top-tier tertiary hospitals, passed review by the National Medical Products Administration's Center for Medical Device Evaluation (NMPA), and officially entered the "green channel" for innovative medical device special review — becoming the first ophthalmic surgical robot to do so in China. It is poised to fill the gap in commercially available domestic ophthalmic surgical robots, offering more precise and safer treatment for over 40 million Chinese patients with fundus diseases.

Digisight Medical's ophthalmic surgical robot featured on CCTV

Additionally, Digisight Medical's general-purpose microsurgical robot in January 2025 successfully performed the world's first robot-assisted deep cervical lymphaticovenous anastomosis (LVA) for Alzheimer's disease, as well as China's first robot-assisted LVA reconstruction for lymphedema. Leveraging Digisight's self-developed micron-level motion control, micro wristed instruments, and flexible grasping technology, the microsurgical robot can perform lymphaticovenous anastomosis at precision levels down to 0.1 mm, overcoming the physiological tremor limitations of traditional surgery and significantly improving safety and accuracy.

Currently, Digisight products have been used to deliver innovative treatments to hundreds of patients across dozens of hospitals, transforming delicate procedures that were difficult or impossible under traditional microscopes into safe, controllable, robot-assisted precision operations — a meaningful convergence of disruptive technology and innovative products that addresses real clinical pain points.

People's Daily reports on Digisight's microsurgical robot

Performing 0.2 mm lymphaticovenous anastomosis at Zhejiang Provincial People's Hospital

Dr. Cui Di, founder of Digisight Medical, stated: "Microsurgery is an extraordinarily difficult and delicate class of procedures that pushes beyond the physiological limits of human hands. Microsurgical robots address rigid needs and offer clear advantages in enhancing micro-manipulation stability, improving surgical precision and degrees of freedom, reaching deep tissues inaccessible to traditional microsurgery, and alleviating physician fatigue during lengthy operations. Digisight Medical's microsurgical robot and related products have already been deployed at dozens of top-tier hospitals, serving hundreds of patients."

Dr. Zhou Mingchuan, VP of Technology at Digisight Medical and researcher at Zhejiang University, stated: "The past 30 years were the internet era; the next 30 years will be the intelligent robotics era. Robots can not only help humanity reach the vast stars, but also connect us to the microscopic world that is difficult to observe with the naked eye or manipulate with bare hands. Robotic micro-manipulation enables humans to perform better at micro-scale dexterous operations, with important applications in medicine, agriculture, and industry. Starting from and continuously deepening its focus on robotic micro-manipulation, Digisight is genuinely helping microsurgeons break through physiological limits, gaining more stable, safe, finely quantified, and visualized operational capabilities — greatly enhancing the operator's control over delicate tissue manipulation."

Going forward, Digisight will continue expanding the application of robotic micro-manipulation technology in ophthalmology and microsurgery, committed to providing high-precision, easy-to-operate, perceivable, and digitized solutions for clinical surgery and life science research. With the support of this new financing round, Digisight believes its products can play an even more important role in human health, benefiting doctors and patients worldwide.